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Agonist-promoted regulation of the uridine nucleotide-
activated human P2Y4 receptor (P2Y4-R) and P2Y6 recep-
tor (P2Y6-R) was studied. Incubation of P2Y4-R-expressing
1321N1 human astrocytoma cells with the cognate agonist
UTP resulted in rapid desensitization of the inositol phos-
phate response and a 50% loss of cell surface receptors. In
contrast, incubation of P2Y6-R-expressing cells with the
cognate agonist UDP caused neither rapid desensitization
nor rapid loss of cell surface receptors. Removal of UTP
from the medium of UTP-pretreated cells resulted in rapid
and complete recovery of surface P2Y4-R even after 12 h of
agonist treatment. Although extended incubation with
UDP also caused a loss of surface P2Y6-R, rapid recovery of
surface P2Y6-R did not occur following removal of agonist.
Pharmacological studies indicated that neither protein ki-
nase C nor other Ca21-activated kinases were involved in
agonist-promoted desensitization or loss of surface P2Y4-R
or P2Y6-R. Mutational analyses were carried out to identify
domains involved in agonist-dependent regulation of
P2Y4-R. Sequential truncation of the carboxyl-terminal do-
main revealed that sequence between amino acids 332 and
343 was necessary for UTP-promoted desensitization and
internalization. Further mutational analyses of the three
serines in this domain confirmed that Ser-333 and Ser-334
play a major role in these agonist-promoted changes in
P2Y4-R. Experiments were carried out with [32P]Pi-labeled
cells to ascertain the role of phosphorylation in regulation
of P2Y4-R. Incubation with UTP for 2 min caused a marked
increase in phosphorylation of both the wild-type P2Y4-R
and the P2Y4–343 truncation mutant. In contrast, no UTP-
promoted phosphorylation of the P2Y4–332 truncation mu-
tant was observed. Taken together, these results demon-
strate differential regulation of uridine nucleotide-
activated P2Y4-R and P2Y6-R and indicate that Ser-333 and
Ser-334 in the carboxyl terminus of P2Y4-R are important
for UTP-dependent phosphorylation, desensitization, and
loss of surface receptors.
Adenine nucleotides function as neurotransmitters in the
peripheral and central nervous systems and as autocrine or
paracrine signaling molecules in most other tissues (1–3). Two
large classes of receptors, consisting of the ligand-gated P2X
receptors and the G-protein-coupled P2Y receptors (4–6), are
broadly distributed and promote a myriad of physiological re-
sponses to ATP and ADP, including neurotransmission, muscle
contraction, immunological responses, and platelet aggregation
(2, 7). A complex family of ecto-enzymes rapidly hydrolyze or
interconvert extracellular nucleotides thereby either terminat-
ing their signaling action or producing an active metabolite of
altered P2 receptor selectivity (8).
The existence of extracellular pyrimidinergic signaling, first
suggested over a decade ago (9–11), was brought into focus in
studies of UTP-promoted second messenger responses (12–16).
UTP was confirmed as an extracellular signaling molecule by
demonstration of regulated release of endogenous UTP (17, 18)
and by cloning of uridine nucleotide-activated G-protein-cou-
pled receptors (19–22). The P2Y2-R, which is equipotently
activated by ATP and UTP, was the first molecularly identified
uridine nucleotide-activated receptor (19). However, the dem-
onstration (23), and then cloning (20–22) of uridine nucleotide-
specific members of the P2Y receptor family placed the pyrim-
idinergic signaling hypothesis on firm ground. The human
P2Y4-R1 is specifically activated by UTP (20, 21, 24) and com-
petitively antagonized by ATP (25); nucleoside diphosphates
are inactive. In contrast, the human P2Y6-R is specifically
activated by UDP and is insensitive to UTP or other triphos-
phates (22, 24).
The biological significance of P2Y receptors that exhibit
strict specificity for either UTP or UDP is not yet understood,
and evidence for physiological release of UDP in concentrations
that activate P2Y6-R is not available. Thus, the extracellular
breakdown of UTP to UDP may provide an important source of
activating agonist for P2Y6-R (26). If metabolic formation of
UDP is important, then temporal differences might be expected
in both the rapidity by which these receptors are activated
upon release of nucleotide and in the length of their activation.
The relative capacity of P2Y4-R and P2Y6-R to undergo ago-
nist-induced desensitization also would interplay with possible
differences in their rapidity and longevity of activation due to
differences in the extracellular presence of their cognate
agonists.
Little is known about the regulation of P2Y-R in general and
of the uridine nucleotide activated P2Y-R in particular. More-
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over, P2Y4-R and P2Y6-R differ markedly in potential sites for
phosphorylation by second messenger-regulated kinases and
GRKs. Thus, we initiated a comparative examination of the
agonist-promoted changes in the activities of these receptors
and of the mechanisms that underlie these changes. Major
differences in the mechanisms of regulation of P2Y4-R versus
P2Y6-R are described below. We also report identification of
two adjacent serines in the carboxyl terminus of the P2Y4-R
receptor that play a major role in agonist-dependent phospho-
rylation, desensitization, and internalization of this receptor.
EXPERIMENTAL PROCEDURES
Construction of Mutant P2Y4-R and P2Y6-R cDNAs—Mutant recep-
tor cDNA constructs were generated by polymerase chain reaction
using cloned Pfu polymerase (Stratagene) and primers that incorpo-
rated an EcoRI or MluI restriction site at the amino terminus and a
XhoI site at the carboxyl terminus. All receptor cDNAs were digested
and ligated into a pLXSN retroviral expression vector that incorporated
an HA epitope tag (YPYDVPDYAS) after the initial methionine residue.
Truncation mutations were made of the P2Y4-R carboxyl terminus
using primers that engineered a stop codon directly downstream of
Ser-332, Ser-343, and Ser-355. PCR products were generated using the
upstream primer 59-CCGCCTCGATCCTCCCTT-39 and the following
downstream primers: 59-GAGACTCGAGTCAGTCCTGGGGGGTG-
GCC-39 for P2Y4/355, 59-GAGACTCGAGTCAATCCTCAGGCAGGGA-
CACTA-39 for P2Y4/343, and 59-GAGACTCGAGTCAGGCAGCCGT-
GCGGGGCT-39 for P2Y4/332. Point mutations were made in the
P2Y4-R carboxyl terminus and P2Y4-R and P2Y6-R using four-primer
PCR. The upstream primer employed for all reactions was 59- CCGC-
CTCGATCCTCCCTT-39, the downstream primer for mutations in the
third intracellular loop was 59-CCTGGGGACTTTCCACAC-39, and the
downstream primer for mutations in the carboxyl terminus was 59-
GACTATGGTTGCTGACTAATTG-39. The following internal primers
were used: 59-TCTCGCCTCCGCGCTCTCCGCACCA-39 and 59-TGGT-
GCGGAGAGCGCGGAGGCGAGA-39 for P2Y4(S243A), 59-CGTGGCA-
AGTCGGCCCGCAT-39 and 59-ATGCGGGCCGACTTGCCACG-39 for
P2Y6(A237S), and 59-CACTAGTGCCAGGGCAGCGGCAGCCGTGCG-
GGGCTG-39 and 59-GCTGCCCTGGCACTAGTGGCCCTGCCTGAGG-
ATAGCAG-39 for P2Y4(S333A, S334A, S339A). P2Y4 S/T-A, a full-
length P2Y4-R construct with 10 serine and threonine residues mu-
tated to alanine, was engineered in a stepwise fashion by first
using four-primer PCR with 59-CCGCCTCGATCCTCCCTT-39 as the
upstream primer, 59-GACTATGGTTGCTGACTAATTG-39 as the
downstream primer, and 59-GGCGGCCGCCCACCTGCAGGCGGCAT-
CCTCAGGCAGGGACAC-39 and 59-TGCAGGTGGGCGGCCGCCCCC-
CAGGACAGT-39 as internal primers. The product from this reaction
was amplified with four-primer PCR, the same upstream and down-
stream primers, and 59-CACTAGTGCCAGGGCAGCGGCAGCCGTGC-
GGGGCTG-39 and 59-GCTGCCCTGGCACTAGTGGCCCTGCCTGAG-
GATGCCG-39 as internal primers. The product from this reaction was
amplified with the following two primers: 59-CCGCCTCGATCCTCCC-
TT-39 and 59-TAGGAGCAGCACAAGCAGCGTCCTGGGGGGCGGC-
C-39 and the final, full-length construct was generated using 59-CCG-
CCTCGATCCTCCCTT-39 and 59-GAGACTCGAGTTACAATCTATCTG-
CTCTAGGAGCAGCACAAGCAGC-39. Additional point mutant con-
structs were made using four-primer PCR and P2Y4/343 as a template.
59-CCGCCTCGATCCTCCCTT-39 and 59-TAGGGGCGGGACTATGGT-
TG-39 were employed as upstream and downstream primers, respect-
ively, and the following internal primers were used: 59-CACTAGTGC-
CAGGGAAGCGGCAGCCGTGC-39 and 59-GCTTCCCTGGCACTAGTG-
TC-39 for P2Y4/343(S333A), 59-CACTAGTGCCAGGGCAGAGGCAGCC-
GTGC-39 and 59-TCTGCCCTGGCACTAGTGTC-39 for P2Y4/343(S334A),
and 59-CACTAGTGCCAGGGCAGCGGCAGCCGTGC-39 and 59-GCTG-
CCCTGGCACTAGTGTC-39 for P2Y4/343(S333A,S334A). P2Y4/343-
(S339A) was generated using full-length P2Y4-R sequence as the
template and 59-CCGCCTCGATCCTCCCTT-39 and 59-GAGACTCG-
AGTCAATCCTCAGGCAGGGCCACTAGTG-39 as upstream and down-
stream primers, respectively. P2Y4/343(S333A,S334A,S339A) was con-
structed with P2Y4(S333A,S334A,S339A) as the template and 59-CCG-
CCTCGATCCTCCCTT-39 and 59-GAGACTCGAGTCAATCCTCAGGC-
AGGGCCACTA-39 as upstream and downstream primers, respectively.
The chimera P2Y6/310-Y4 was generated with four-primer PCR using
59-CCGCCTCGATCCTCCCTT-39 and 59-CCTGGGGACTTTCCACA-
C-39 as upstream and downstream primers, respectively, and 59-CCG-
GCGGAACTTCTTCTGG-39 and 59-CCAGAAGAAGTTCCGCCGGCAG-
CTCCGTCAGCTCTGTG-39 as internal primers.
Cell Culture and Expression of Receptor Constructs—P2Y-R-express-
ing 1321N1 human astrocytoma cells were grown in DMEM with 4.5
g/liter glucose (Life Technologies, Inc.) supplemented with 5% FBS
(Hyclone) in a 37 °C humidified atmosphere with 5% CO2 and 95% air.
Retrovirus packaging and cell infections were performed as previously
described (27). Following infection, receptor-expressing 1321N1 cells
were selected in medium containing 1 mg/ml G418 (Life Technologies,
Inc.). Stable cell lines were maintained in medium containing 0.6 mg/ml
G418.
Radioimmunoassay for Detection of Surface P2Y-R—P2Y-R-express-
ing 1321N1 cells were seeded at 3 3 105 cells/well in 12-well plates
(Corning/Costar) coated with 10 mg/ml fibronectin (Collaborative Bio-
products). Assays were performed on confluent cells 2 days after plat-
ing. For most experiments, assays were initiated by replacing the me-
dium with DMEM containing 50 mM HEPES (pH 7.5), and equilibrating
for 1 h at 37 °C prior to assay of agonist-promoted responses. Drug
incubations of longer than 1-h duration were performed in a humidified,
37 °C/5% CO2 incubator without a medium change. Drug treatments
were terminated by placing plates in an ice bath, aspirating the me-
dium, adding 2% cold paraformaldehyde (Sigma), and incubating at
room temperature for 10 min. Following a wash with HBSS containing
Ca21 and Mg 21, HEPES/DMEM with 10% heat-inactivated FBS was
added to each well for 30 min. Anti-HA.11 raw ascites fluid (BabCo/
Covance) was added without changing the medium to a final concen-
tration of 1:1000 for 1 h. Cells were washed two times with HBSS
containing Ca21 and Mg21, followed by addition (typically 100,000
cpm/assay) of 125I-rabbit anti-mouse antibody (PerkinElmer Life Sci-
ences) diluted in HEPES/DMEM with 10% heat-inactivated FBS to a
concentration of 1:500. Following a 2-h incubation at room temperature,
the cells were washed twice with HBSS containing Ca21 and Mg21.
Cells were solubilized with 1 M NaOH and transferred to glass tubes for
quantitation of radioactivity by gamma counting.
In Vivo Labeling and Immunoprecipitation of P2Y4-R—Confluent
100-mm dishes of P2Y4-R-expressing cells were washed with phos-
phate-free DMEM and incubated in phosphate-free DMEM for 1 h in a
37 °C humidified incubator with 5% CO2 and 95% air. Cells were
labeled with 500 mCi of [32P]orthophosphate for 3 h. Following labeling,
cells were treated with UTP for 2 min, transferred to an ice bath, and
washed with ice-cold PBS. Ice-cold lysis buffer containing 50 mM Tris-
HCl (pH 7.4), 100 mM NaCl, 5 mM EDTA, 50 mM NaF, 10 mM sodium
pyrophosphate, 200 mM Na3VO4, 1% Triton X-100, 200 mM phenylmeth-
ylsulfonyl fluoride, 10 mg/ml benzamidine A, 1 mM pepstatin A, 4.3
mg/ml leupeptin, and 10 mg/ml TPCK was added to each dish for 5 min.
The cell extracts were transferred to screw cap tubes, rocked for 1.5 h at
4 °C, and centrifuged at 13,000 3 g for 30 min at 4 °C. The resultant
supernatants were transferred to fresh tubes containing 30 ml of protein
A/G PLUS-agarose beads (Santa Cruz Biotechnology, Inc.) that were
preblocked with 1% BSA for 30 min. Following rocking for 45 min at
4 °C, the samples were centrifuged for 15 s at 13,000 3 g, and the
supernatants were transferred to tubes containing 2 ml of anti-HA.11
raw ascites fluid (BabCo/Covance) and 50 ml of preblocked protein A/G
beads. Tubes were rocked for 1.5 h at 4 °C followed by a quick centrif-
ugation. The pelleted beads were washed twice with the Triton X-100-
containing lysis buffer and resuspended in 40 ml of 23 Laemmli sample
buffer. Samples were loaded onto a 9% polyacrylamide gel, electro-
phoresed, and transferred to nitrocellulose. Radioactivity associated
with the immunoprecipitated P2Y4-R was measured with a phosphor-
imaging screen. Immunoblots were generated by blocking with 3%
BSA/TBST for 1 h or overnight and incubating with 1:1000 anti-HA-
purified monoclonal antibody (Babco/Covance) in 3% BSA/TBST for 2 h.
Blots were washed four times with TBST followed by a 2.5-h incubation
with 1:10,000 anti-mouse horseradish peroxidase-conjugated antibody
in 3% BSA/TBST. Following four washes with TBST, protein bands
were visualized with ECL reagent.
Inositol Phosphate Assay—P2Y-R-expressing 1321N1 human astro-
cytoma cells were seeded in 24-well plates at 1 3 105 cells/well 2 days
prior to assay. The evening before each assay, the medium was removed
and replaced with 200 ml of inositol-free DMEM containing 2 mCi/ml
[3H]inositol. Drug incubations were performed in a 37 °C water bath in
the presence of 10 mM LiCl and terminated by addition of 0.9 ml of 50
mM ice-cold formic acid. After a 20-min incubation on ice, 0.3 ml of 150
mM ammonium formate was added to each well. The supernatant
from each well was transferred to Dowex AG1-X8 columns, and total
[3H]inositol phosphates were quantitated as previously described
(23, 24).
Data Analysis—All experiments were repeated at least three times
in triplicate assay except where indicated in the figure legends. Results
are presented as the mean 6 S.E.
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RESULTS
Agonist-induced Desensitization and Loss of Cell Surface
P2Y4-R and P2Y6-R—Agonist-induced phosphorylation of ser-
ine and threonine residues in the third intracellular loop and
carboxyl terminus has been implicated in desensitization and
subsequent internalization of a broad range of G-protein-cou-
pled receptors (28, 29). Although the P2Y4-R has multiple
putative phosphorylation sites in these domains, the P2Y6-R
contains only a single threonine residue in the carboxyl termi-
nus, suggesting that these two uridine nucleotide-activated
receptors differ significantly in their regulatory mechanisms.
To test this hypothesis we examined agonist-induced desensi-
tization by quantitating the rate of accumulation of total ino-
sitol phosphates in the presence of LiCl and examined agonist-
dependent loss of cell surface P2Y-R utilizing a “surface
binding assay” that employs HA-antibody followed by a 125I-
labeled secondary antibody (see “Experimental Procedures”).
Human 1321N1 astrocytoma cells stably expressing either
P2Y4-R or P2Y6-R were labeled with [3H]inositol, and agonist-
induced desensitization was assessed. The rate of inositol phos-
phate accumulation in P2Y4-R-expressing cells rapidly de-
clined in the presence of UTP, reaching a near steady state
within 10 min (Fig. 1). In contrast, incubation of P2Y6-R-
expressing 1321N1 cells with UDP resulted in a linear accu-
mulation of inositol phosphates for at least 30 min (Fig. 1 and
data not shown). Thus, as was reported previously by Robaye et
al. (30), P2Y4-R undergoes rapid agonist-induced desensitiza-
tion, whereas P2Y6-R fails to desensitize, even after 30 min of
agonist incubation.
The surface binding assay was employed to determine
whether the marked differences in capacity of P2Y4-R and
P2Y6-R to undergo desensitization were reflected in agonist-
dependent changes in surface receptors. Incubation of P2Y4-R-
expressing cells with UTP for 20 min resulted in an ;50%
decrease in the amount of surface P2Y4-R (Fig. 2). The EC50
(886 6 300 nM) of UTP for inducing loss of surface P2Y4-R
during a 20-min incubation (data not shown) was similar to the
EC50 (541 6 200 nM) of UTP for promotion of inositol phosphate
accumulation and the EC50 of UTP (780 6 60 nM (25)) for
stimulation of Ca21 mobilization. In contrast to the changes
observed in surface P2Y4-R, a 20-min incubation of P2Y6-R-
expressing cells with UDP had essentially no effect on surface
receptor levels (Fig. 2). Thus, differences in the capacity of
these receptors to undergo rapid agonist-induced desensitiza-
tion were paralleled by differences in agonist-induced loss of
surface receptors.
Extended time courses for agonist-induced loss of surface
receptors were generated to further compare P2Y4-R and
P2Y6-R. P2Y4-R levels decreased rapidly during agonist incu-
bation reaching a near steady state within 10 min that de-
creased very slowly if at all over the ensuing 12 h (Fig. 3).
Although agonist-promoted changes in surface P2Y6-R oc-
curred more slowly, with extended incubation (.1 h), decreases
in the surface levels of this uridine nucleotide-activated recep-
tor also were observed (Fig. 3).
To study the reversibility of agonist-induced loss of surface
receptors, we took advantage of the nucleotide-hydrolyzing ac-
tivity of the enzyme apyrase. This approach was necessary,
because antagonists of P2Y4-R or P2Y6-R are not available,
and mechanical stimulation caused by medium changes of cul-
tured cells results in release of large amounts of cellular UTP
into the medium (17, 18). The reversibility of the loss of surface
P2Y4-R or P2Y6-R was examined after various times of incu-
bation with UTP or UDP followed by addition of apyrase at a
concentration that completely hydrolyzed nucleotide within 1
min (data not shown). Surprisingly, surface P2Y4-R returned
to control levels within 30 min of addition of apyrase, irrespec-
tive of the time (up to 12 h) of preincubation with agonist (Fig.
4A). The agonist-promoted loss of cell surface P2Y4-R and the
complete recovery of P2Y4-R to the surface after hydrolysis of
agonist in the medium suggest efficient recycling of internal-
ized receptors. This possibility was supported by the fact that
cycloheximide at a concentration (10 mg/ml) that inhibited pro-
tein synthesis had no effect on the rapid recovery of P2Y4-R
after removal of agonist from the medium (data not shown).
Direct evidence for recycling was provided by experiments in
which P2Y4-R were prelabeled with primary antibody prior to
addition of agonist. Cell surface immunoreactivity moved to an
intracellular compartment following addition of agonist (40 6
15% of control after 20 min in the presence of 100 mM UTP).
Antibody-bound receptors then returned to the cell surface
after agonist removal by addition of apyrase (95 6 2% of control
levels after removal of agonist for 60 min). The reversibility of
FIG. 1. Agonist-promoted inositol phosphate accumulation in
P2Y4-R- and P2Y6-R-expressing cells. P2Y4-R- and P2Y6-R-ex-
pressing 1321N1 cells were prelabeled with [3H]inositol and then incu-
bated in the presence of 10 mM LiCl and 100 mM UTP (P2Y4-R), or 100
mM UDP (P2Y6-R). Total [3H]inositol phosphate accumulation was
quantitated at the indicated times.
FIG. 2. Agonist-promoted effects on cell surface P2Y4-R and
P2Y6-R. P2Y4-R and P2Y6-R-expressing 1321N1 cells were incubated
in the absence (open bars) or presence (filled bars) of 100 mM UTP and
100 mM UDP, respectively, for 10 min. Surface P2Y-R were quantitated
using anti-HA antibody followed by a 125I-labeled secondary antibody.
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UDP-induced changes in the cell surface levels of P2Y6-R also
was studied after long-term agonist treatment. In marked con-
trast to P2Y4-R, removal of UDP from the medium with
apyrase after 3-h preincubation did not result in rapid recovery
of P2Y6-R to the cell surface (Fig. 4B). Thus, in the presence of
UTP P2Y4-R are internalized and sequestered in an intracel-
lular pool from which receptors rapidly recycle to the cell sur-
face once agonist is removed. In contrast, P2Y6-R are more
slowly lost from the cell surface in the presence of agonist and
fail to rapidly recycle once agonist is removed from the
medium.
Potential Regulation of P2Y4-R and P2Y6-R by Second Mes-
senger-regulated Kinases—P2Y4-R and P2Y6-R are both cou-
pled to Gq and phospholipase C (6), and PKC has been broadly
implicated in feed-back regulation of the inositol lipid signaling
pathway (31). Moreover, PKC has been shown to phosphorylate
a number of Gq/phospholipase C-linked GPCR (32–34). Be-
cause the P2Y4-R contains a strong PKC consensus sequence in
its third intracellular loop and several weaker sequences in its
carboxyl terminus, we investigated the potential involvement
of PKC in agonist-promoted loss of surface P2Y4-R and
P2Y6-R. Incubation of P2Y4-R-expressing 1321N1 cells with
the phorbol ester activator of PKC, PMA, caused only a small
loss of surface P2Y4-R compared with that observed during a
parallel incubation with UTP (Fig. 5A). Although the PKC
inhibitor, bisindolemaleimide, blocked the small PMA-induced
changes, it had no effect on UTP-induced loss of surface P2Y4-R
(Fig. 5B). Down-regulation of PKC by overnight incubation
with 1 mM PMA also had no effect on the time course of occur-
rence or extent of UTP-promoted loss of cell surface P2Y4-R
(Fig. 5C). In contrast, down-regulation of PKC blocked the
acute effects of PMA on cell surface P2Y4-R (Fig. 5C). As was
observed with short-term incubation with UDP, incubation of
P2Y6-R-expressing cells with PMA had no effect on cell surface
receptors (Fig. 5A).
The potential role of the PKC-consensus site (RLRS) in the
third intracellular loop of the P2Y4-R also was examined. Mu-
tation of this serine to alanine (P2Y4(S243A); see Fig. 6) failed
to inhibit agonist-induced internalization of P2Y4-R (data not
shown). Interestingly, although this serine is lacking in the
third cytoplasmic loop of the P2Y6-R, the adjoining residues
are conserved. Thus, we mutated the corresponding residue of
the P2Y6-R to serine (P2Y6/A237S; see Fig. 6) to recapitulate
the sequence found in the P2Y4-R. This mutation failed to
confer in the P2Y6-R a capacity to undergo rapid agonist-de-
pendent loss of surface receptors (data not shown). Therefore,
this potential site for PKC phosphorylation is not involved in
agonist-induced changes in surface levels of P2Y4-R, and engi-
neering this site into the P2Y6-R also did not uncover UDP-
induced loss of surface receptors. Taken together, these results
support the idea that mechanisms largely unrelated to PKC
mediate agonist-promoted P2Y4-R sequestration. No effects on
agonist-promoted loss of surface P2Y4-R were observed after
elevation of Ca21 levels with ionomycin or after increasing
cyclic AMP levels with forskolin (data not shown).
Identification of Regulatory Sites in the Carboxyl-terminal
Domain of the P2Y4-R by Mutational Analysis—A series of
receptor mutants was constructed with the goal of identifying
the regions and residues important for regulation of P2Y4-R
signaling (Fig. 6). Each mutant P2Y4-R was stably expressed in
1321N1 cells, and its capacity to promote inositol lipid hydrol-
ysis was compared with that of the wild-type P2Y4-R. Concen-
tration effect curves for UTP at wild type and two mutant
P2Y4-R are presented in Fig. 7. The EC50 values for stimula-
tion (5-min assay) of inositol phosphate accumulation by UTP
ranged from 200 to 2000 nM for all of the mutant receptors
reported in this study (data not shown). The EC50 for UTP (in
a 5-min assay) at the wild type P2Y4-R stably expressed in
parallel with these various mutants was 440 6 250 nM. The
maximal effect of 100 mM UTP for stimulation of inositol phos-
phate accumulation in a 5-min assay (0.4–2.5% conversion of
FIG. 3. Time course of agonist-promoted decrease in cell sur-
face P2Y4-R and P2Y6-R. P2Y4-R- and P2Y6-R-expressing 1321N1
cells were incubated with 100 mM UTP (f) and 100 mM UDP (M),
respectively, for the indicated times. Surface P2Y-R were quantitated
using anti-HA antibody followed by a 125I-labeled secondary antibody.
FIG. 4. Recovery of surface P2Y4-R and P2Y6-R. A, P2Y4-R-
expressing 1321N1 cells were incubated for various times with 100 mM
UTP. At the indicated times, apyrase (at a concentration that immedi-
ately hydrolyzed the UTP) was added to the medium, and cell surface
P2Y4-R were measured 30 or 60 min later using anti-HA antibody
followed by a 125I-labeled secondary antibody. The data are from trip-
licate assays in an experiment that was representative of two similar
experiments. B, P2Y6-R-expressing 1321N1 cells were incubated in the
absence (control) or presence of 100 mM UDP for 1 or 3 h. Apyrase (at a
concentration that immediately hydrolyzed UDP) then was added to the
medium, and cell surface P2Y6-R were measured 30 or 60 min later
using anti-HA antibody followed by 125I-labeled secondary antibody.
The data are the mean 6 S.E. and are representative of results from
three experiments.
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[3H]inositol lipids into [3H]inositol phosphates) with the mu-
tant receptors also was within the range of maximal effect
(0.99 6 0.42% conversion) observed with 100 mM UTP at the
wild type P2Y4-R in a 5-min assay. Thus, each mutant receptor
promoted inositol lipid hydrolysis with characteristics similar
to that of the wild type receptor. The enhanced maximal re-
sponse of the P2Y4/332 truncation mutant illustrated in Fig. 7
apparently occurs due to the fact that this receptor does not
desensitize (see data and discussion below).
The carboxyl-terminal region of the P2Y4-R is ;55 amino
acids in length and contains 11 serines and threonines as
potential sites for phosphorylation. To determine whether the
carboxyl terminus is important in P2Y4-R desensitization and
trafficking, a series of truncations was made after residues 355,
343, and 332 (Fig. 6). Truncations of the carboxyl terminus that
removed the final 11 amino acids (and four serines/threonines),
i.e. P2Y4/355 (data not shown), or final 23 amino acids (and
seven serines/threonines), i.e. P2Y4/343, had no effect on ago-
nist-induced loss of cell surface P2Y4-R (Fig. 8) or desensitiza-
tion (Fig. 9). In contrast, removal of an additional 11 residues
(and three serines), i.e. P2Y4/332, markedly inhibited agonist-
induced loss of cell surface P2Y4-R (Fig. 8) and prevented
agonist-induced desensitization (Fig. 9; also see Fig. 7). There-
fore, residues between 332 and 343 in the carboxyl terminus of
P2Y4-R are required for agonist-induced desensitization and
loss of surface receptors. Although these data establish the
P2Y4-R carboxyl terminus as a critical region for agonist-in-
duced regulation of this receptor, chimeric addition of the
P2Y4-R carboxyl terminus to P2Y6-R, i.e. P2Y6/310-Y4 (Fig. 6),
failed to confer UDP-induced loss of surface receptors to the
chimeric P2Y6-R (data not shown).
The data from the carboxyl terminus truncation studies sug-
gest that amino acids within the region that differs between the
two mutants, P2Y4/343 and P2Y4/332, are crucial for regula-
tion of P2Y4-R signaling. This region contains three putative
phosphorylation sites, i.e. Ser-333, Ser-334, and Ser-339. To
evaluate their role in regulation of P2Y4-R these serines were
mutated to alanines (P2Y4/S333A,S334A,S339A). The capacity
of this mutant P2Y4-R to undergo agonist-induced desensitiza-
tion (Fig. 9) or agonist-promoted loss of surface receptors (Fig.
10) was greatly reduced but not completely inhibited. Because
alternative sites in the carboxyl terminus, i.e. the seven
serines/threonines carboxyl-terminal to Ser-339, could be phos-
phorylated after mutation of Ser-333, Ser-334, and S339, the
truncation mutant P2Y4/343 was used as the “wild type” se-
quence to assess more directly the role(s) of amino acids be-
tween positions 332 and 343. All three of the serines were
mutated individually in the truncated receptor, all three
serines were mutated simultaneously in a triple mutant, and a
double mutant of the serines at positions 333 and 334 also was
constructed. Mutation of individual serines did not inhibit ag-
onist-induced loss of surface receptors. In contrast, simultane-
ous mutation of Ser-333 and Ser-334 or of Ser-333, Ser-334,
and S339 reduced the capacity of UTP to induce loss of surface
receptors by ;80% (Fig. 11). The inhibition observed with these
two mutants was similar to that seen with a full-length con-
struct, designated S/T-A (see Fig. 6), containing mutations to
alanine at all potential phosphorylation sites carboxyl-terminal
to residue 332 (Fig. 11). Taken together, these data illustrate
that serines 333 and 334 are important sites for agonist-
induced desensitization and loss of surface P2Y4-R.
Agonist-promoted Phosphorylation of P2Y4-R—Experiments
were carried out to demonstrate directly that the P2Y4-R is
phosphorylated in an agonist-dependent fashion and to estab-
lish whether the regulatory domain identified by mutational
analysis also contributes to the residue(s) responsible for this
phosphorylation. Cells expressing HA-tagged P2Y4-R were pre-
labeled with [32P]Pi and then incubated with UTP for 2 min.
The extent of [32P]phosphorylation of P2Y4-R was established
as described under “Experimental Procedures.” A small
amount of 32P-phosphorylation of P2Y4-R was detected in the
absence of added agonist (Fig. 12). This phosphorylation was
not observed in cells not expressing P2Y4-R, and therefore,
either represents basal P2Y4-R phosphorylation unrelated to
P2Y4-R activation or occurs due to the presence of constitu-
tively released extracellular UTP as we have recently described
(26). Addition of UTP for 2 min resulted in a marked increase
in P2Y4-R phosphorylation (Fig. 12). This agonist-promoted
FIG. 5. Pharmacological analyses of the potential role of PKC
in regulation of cell surface P2Y4-R and P2Y6-R. A–C, surface
levels of P2Y-R were measured using an anti-HA antibody followed by
a 125I-labeled secondary antibody. A, P2Y4-R (light bar) or P2Y6-R
(dark bar)-expressing 1321N1 cells were incubated with vehicle
(DMSO) or 10 mM PMA for 10 or 20 min or with 100 mM UTP (agonist)
or 100 mM UDP (agonist) for 20 min. B, P2Y4-R-expressing 1321N1 cells
were incubated for 20 min with 100 mM UTP, 10 mM PMA, vehicle 1 100
mM UTP (D1U), 10 mM bisindolmaleimide 1 100 mM UTP (B1U), or 10
mM bisindolemaleimide 1 10 mM PMA (B1P). C, P2Y4-R-expressing
1321N1 cells were incubated in the absence (light bar) or presence (dark
bar) of 1 mM PMA overnight to down-regulate PKC. Cells then were
incubated with 100 mM UTP for the indicated times or with 10 mM PMA
for 30 min.
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phosphorylation apparently does not occur in the final seven
serines/threonines of the carboxyl terminus, because a similar
amount of agonist-dependent phosphorylation was observed
with the P2Y4/343-R truncation mutant. In contrast, the ca-
pacity of UTP to induce phosphorylation was completely lost
with the P2Y4/332 truncation mutant (Fig. 12). These results
indicate that phosphorylation occurs on one or more of the
three serines present between residues 332 and 343 in the
carboxyl terminus. Together with the mutational analyses pre-
sented above, these results indicate that Ser-333 and Ser-334
are key regulatory residues in the events of agonist-induced
phosphorylation, desensitization, and loss of cell surface
P2Y4-R.
DISCUSSION
The observation of a broad range of uridine nucleotide-acti-
vated physiological responses (2), the cloning of two receptors
that are specifically activated by uridine nucleotides (20–22),
and the demonstration of regulated release of cellular UTP (17,
18) establish pyrimidinergic signaling as a physiologically im-
portant regulatory pathway. The UTP versus UDP specificity of
P2Y4-R versus P2Y6-R adds potential complexity to pyrimidin-
ergic signaling, and we have demonstrated here that these two
P2Y-R exhibit very different regulatory properties. The P2Y4-R
undergoes rapid agonist-induced desensitization but does not
down-regulate. In contrast, the P2Y6-R does not undergo rapid
agonist-induced desensitization but does down-regulate. Delin-
eation of the molecular basis of the very different modes of
regulation of these two uridine nucleotide-activated receptors
FIG. 6. Mutations of P2Y4-R and
P2Y6-R. A series of deletions and muta-
tions was made in the carboxyl terminus
and third intracellular loop of the human
P2Y4-R and human P2Y6-R.
FIG. 7. Agonist-promoted inositol phosphate accumulation in
P2Y4-, P2Y4/343-, and P2Y4/332-R-expressing cells. P2Y4-, P2Y4/
343-, and P2Y4/332-R-expressing 1321N1 cells were prelabeled with
[3H]inositol and then incubated in the presence of 10 mM LiCl and the
indicated concentrations of UTP for 5 min. Total [3H]inositol phosphate
accumulation was measured and divided by the total labeling of [3H]-
inositol lipids to determine the percent conversion to [3H]inositol
phosphates.
FIG. 8. Truncation of the carboxyl terminus prevents UTP-
promoted loss of cell surface P2Y4-R. 1321N1 Cells stably express-
ing wild type P2Y4-R (f), P2Y4-R truncated at amino acid 343 (Œ), or
P2Y4-R truncated at amino acid 332 (ƒ) were incubated for the indi-
cated times with 100 mM UTP. Cell surface receptors were detected
using anti-HA antibody followed by 125I-labeled secondary antibody.
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will be important to establish. In the current study we have
shown that agonist-dependent phosphorylation of either of two
adjacent serines in the carboxyl terminus of P2Y4-R contrib-
utes an initiating step in both desensitization and internaliza-
tion of this receptor.
The rapidly occurring desensitization of P2Y4-R is a predict-
able regulatory response of a GPCR and confirms results pre-
viously reported by Robaye et al. (30) for P2Y4-R. Our kinetic
analyses were of insufficient detail to resolve the time course of
occurrence of desensitization from that of loss of surface recep-
tors, but desensitization occurred at least as rapidly as did the
receptor trafficking response. Agonist-induced desensitization
of phospholipase C-linked GPCR has been exceptionally diffi-
cult to quantitate (35), because activity cannot be assessed in
membranes prepared from agonist-preincubated cells as is the
case with studies of adenylyl cyclase-linked receptors. Meas-
urement of intact cell Ins(1,4,5)P3 levels (35–39) may have
certain advantages over quantitation of total inositol phos-
phates in the presence of LiCl as in the current study. Desen-
sitization of the Ins(1,4,5)P3 response almost certainly occurs
faster than that revealed here in a measurement that includes
not only Ins(1,4,5)P3 but also all of its downstream metabolites.
Thus, we only can conclude that agonist-induced desensitiza-
tion of P2Y4-R is very rapid and likely occurs prior to loss of
surface receptors. That agonist-stimulated accumulation of to-
tal inositol phosphates is essentially linear during activation of
P2Y6-R expressed in the same cells, provides validation of the
qualitative, if not quantitative, aspects of our analyses.
The P2Y4/343 carboxyl-terminal truncation mutant retained
all of the phenotypical responses of the wild type receptor. In
contrast, although UTP activated the P2Y4/332 mutant with
properties similar to the wild type receptor, this truncated
receptor essentially lost its capacity to undergo UTP-induced
desensitization or loss of surface receptors. Although other
residues in the 332 to 343 domain could provide these regula-
tory properties, the serines at positions 333, 334, and 339 are
potential targets for kinase-promoted phosphorylation. Our
studies showed for the first time that agonist-dependent phos-
phorylation occurs in a P2Y-R (Fig. 12). Moreover, the occur-
rence of UTP-stimulated phosphorylation in the P2Y4/343
truncation mutant but not in the P2Y4/332 truncation mutant
confirms that the domain between residues 332 and 343 pro-
vides the principle sites of agonist-dependent phosphorylation.
Mutational analyses of individual or combinations of serines in
this domain indicate that Ser-333 and Ser-334 are the impor-
tant sites of regulation and strongly suggest that phosphoryl-
ation of either of these two serines is a key step in agonist-de-
pendent desensitization and loss of surface P2Y4-R. However,
our results do not rule out an additional contributing role of
phosphorylation at residues elsewhere in P2Y4-R.
Although the P2Y4-R exhibits a commonly described pheno-
type of rapid desensitization and loss of surface receptors, it is
unusual in that agonist-promoted down-regulation of this re-
ceptor apparently does not occur. That is, following agonist
removal from the medium (after times of preincubation up to
12 h) surface receptors were replenished within 30–60 min of
incubation. Such results could be a vagary of a cell line engi-
neered to express a recombinant receptor. However, P2Y6-R
and P2Y2-R (40) expressed under the same conditions in
1321N1 cells (and apparently to similar levels as P2Y4-R) both
down-regulate. We also have extensively studied down-regula-
tion of the endogenous b2-adrenergic receptor (41, 42) and M3
muscarinic receptor (43, 44) in this same cell line. Thus, the
P2Y4-R is a GPCR that both rapidly desensitizes and rapidly
recovers from desensitization irrespective of the length of time
of activation. It will be important to determine both the phys-
iological significance and structural basis for this unusual
property of P2Y4-R.
FIG. 9. Agonist-promoted inositol phosphate accumulation in
cells expressing mutant P2Y4-R. 1321N1 cells stably expressing
wild type P2Y4-R (f), P2Y4-R truncated at amino acid 343 (Œ), P2Y4-R
truncated at amino acid 332 (ƒ), or P2Y4-R with serine to alanine
mutations at residues 333, 334, and 339 (E) were prelabeled with
[3H]inositol. The cells were then challenged with 100 mM UTP in the
presence of 10 mM LiCl for the indicated times, and total [3H]inositol
phosphates were quantitated.
FIG. 10. Agonist-promoted loss of cell surface P2Y4-R. 1321N1
cells stably expressing either wild type P2Y4-R (f) or a P2Y4-R with
serine to alanine mutations at residues 333, 334, and 339 (E) were
incubated with 100 mM UTP for the indicated times. Surface P2Y4-R
were quantitated using an anti-HA antibody followed by 125I-labeled
secondary antibody.
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The P2Y6-R falls into a relatively small group of GPCR that
do not undergo rapid agonist-induced desensitization. This ob-
servation is not entirely surprising, because the P2Y6-R lacks
serines and threonines in its third cytoplasmic loop and only a
single threonine occurs in the carboxyl-terminal domain. Two
serines and two threonines are present in the first cytoplasmic
loop, but this domain has not been predictably important in
GPCR coupling to heterotrimeric G-proteins or in their agonist-
dependent regulation. Simple replacement of the carboxyl-ter-
minal domain of P2Y6-R with that of P2Y4-R did not confer to
P2Y6-R a capacity to undergo rapid agonist-induced loss of
surface receptors. It is uncertain whether such results reflect a
regulation-resistant contribution of noncarboxyl-terminal se-
quence of P2Y6-R, or whether they simply reflect lack of proper
structural context in which the phosphorylation of Ser-333 and
Ser-334 apparently produce signals for desensitization/inter-
nalization in the P2Y4-R protein.
The overriding view of agonist-induced regulatory changes in
GPCR signaling has followed from studies of the adenylyl cy-
clase-coupled b2-adrenergic receptor (45, 46). The intuitive
model of regulation is one of second messenger-regulated ki-
nases immediately downstream of GPCR feeding back to reg-
ulate the activities of cohort proteins of the pathway. This
model has been substantiated in studies of the b2-adrenergic
receptor by demonstrating that cyclic AMP-dependent protein
kinase is in part responsible for agonist-induced desensitiza-
tion (47–49). However, the dominant concept is that members
of the GRK family of kinases catalyze receptor phosphorylation
to provide the major initiating event in agonist-dependent re-
ceptor desensitization and internalization (28, 29).
As with receptor-regulated adenylyl cyclase, much of the
early thinking on regulation of receptor-promoted inositol lipid
signaling included models involving protein kinase C-mediated
feed-back regulation of responsiveness. This view was sup-
ported by large inhibitory effects of phorbol ester activators of
PKC on receptor-stimulated inositol phosphate accumulation
FIG. 11. Agonist-promoted loss of
surface receptors in cells expressing
truncated/mutated P2Y4-R. 1321N1
cells stably expressing mutant P2Y4-R
were incubated with 100 mM UTP for 20
min. Surface P2Y4-R were quantitated
using an anti-HA antibody followed by
125I-labeled secondary antibody.
FIG. 12. Agonist-promoted phos-
phorylation of wild type P2Y4 and
mutant receptors. Wild type 1321N1
cells (WT) or 1321N1 cells stably express-
ing P2Y4-, P2Y4/343-, and P2Y4/332-R
were labeled with 500 mCi of [32P]
orthophosphate and incubated with 100
mM UTP for 2 min. Cells were lysed, and
receptors were immunoprecipitated, re-
solved on SDS-polyacrylamide gel electro-
phoresis, and transferred to nitrocellu-
lose. A PhosphorImager was used to
measure receptor phosphorylation. The
data are presented as a densitometric
scan of gels from a single experiment and
as bar graphs of densitometric quantita-
tion averaged from two experiments.
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(50–52), although it could be argued that the extent of PKC
activation by PMA greatly exceeds that normally occurring
through receptor-promoted activation of phospholipase C. Ex-
periments utilizing pharmacological inhibition or down-regula-
tion of PKC clearly confirmed a role for this second messenger-
regulated kinase in agonist-promoted desensitization of
inositol lipid signaling (31, 52). However, very few of these
studies established that the effects of PKC were at the level of
the involved GPCR, and PKC could act at multiple levels in the
inositol lipid signaling pathway. For example, phospholipase
Cb is phosphorylated by PKC, and its activity is inhibited (53,
54). Nonetheless, several phospholipase C-linked GPCR are
phosphorylated in response to activation of protein kinase C
(32–34).
The presence of a potential consensus site (S243) for PKC
phosphorylation in the carboxyl-terminal portion of the third
cytoplasmic loop of P2Y4-R suggested that PKC might play a
role in the marked agonist-induced desensitization and loss of
cell surface receptors that occurs upon activation of this recep-
tor. However, incubation of P2Y4-R expressing cells with PMA
did not mimic these UTP-promoted effects, and neither down-
regulation of PKC nor pharmacological inhibition of its activity
altered the time course or extent of agonist promoted loss of
surface P2Y4-R. Moreover, serine to alanine mutation of S243
did not modify agonist-dependent regulatory effects. Thus, al-
though UTP induces profound changes in P2Y4-R, little or none
of these effects follow from a feed-back involvement from its
most proximally activated protein kinase. Because ionomycin
also failed to induce changes in UTP responsiveness or modify
those occurring during incubation with UTP, Ca21/calmodulin-
regulated kinases also are not involved. GRKs recently have
been implicated in regulation of Gq/phospholipase C-coupled
GPCR (29, 55–57), and our experiments that exclude PKC in
regulation of P2Y4-R indirectly suggest that GRKs also regu-
late P2Y4-R. However, coexpression of GRK2 with P2Y4-R in
Cos-7 cells had no effect on UTP-dependent desensitization or
loss of surface receptors whereas in parallel experiments GRK2
expression markedly augmented desensitization and internal-
ization of the P2Y2-R.2 Perhaps another GRK family kinase,
e.g. GRK5, is involved in regulation of P2Y4-R. Alternatively,
casein kinase 1a catalyzes agonist-dependent phosphorylation
and regulation of the Gq/phospholipase C-coupled M3-mus-
carinic receptor, and potentially other Gq-linked receptors
(58, 59).
The P2Y-R family is comprised of a group of five Gq/phos-
pholipase C-linked GPCR that exhibit novel selectivity for ex-
tracellular adenine and uridine di- and triphosphates. The
ATP- and UTP-activated P2Y2-R was shown previously to un-
dergo agonist-induced internalization (40, 60), and Garrad et
al. (60) reported that the capacity of UTP to induce P2Y2-R
sequestration was reduced by truncation of the carboxyl termi-
nus. The current work reveals that the subfamily of two pyri-
midinergic P2Y-R exhibit very different properties of regula-
tion and that each of these receptors exhibits a property of
regulation not common among GPCR. Although our work has
not established the identity of the kinase involved in regulation
of P2Y4-R, it identifies in P2Y-R for the first time sites of
phosphorylation important for agonist-dependent regulation of
receptor responsiveness and cellular translocation. It will be
important to establish whether phosphorylation per se is suffi-
cient to functionally uncouple P2Y4-R from Gq and to establish
the role this phosphorylation plays, for example, in interaction
with arrestin, in internalization, and in a recycling response
that rapidly and completely replenishes surface P2Y4-R even
during extended activation of the receptor.
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